Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma
JOURNAL OF CLINICAL LABORATORY ANALYSIS, vol.31, no.6, 2017 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 31 Issue: 6
- Publication Date: 2017
- Doi Number: 10.1002/jcla.22110
- Journal Name: JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Keywords: papillary thyroid cancer, single nucleotide polymorphism, vascular endothelial growth factor, FACTOR GENE POLYMORPHISMS, BREAST-CANCER, SERUM THYROTROPIN, FACTOR VEGF, EXPRESSION, PROGNOSIS, THYROGLOBULIN, ASSOCIATION, DISEASE, LEVEL
- Istanbul University Affiliated: Yes
Abstract
BackgroundPapillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Vascular endothelial growth factor (VEGF) is a mediator implicated with cell proliferation, differentiation and migration, and monocyte/macrophage chemotaxis. In present study, we aimed to investigate the relationship between VEGF gene polymorphisms (G+405C, T-460C, and A-2578C) and PTC susceptibility.